Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Schweinfurthin-3114 (S-3114) is a natural product-derived small molecule belonging to the schweinfurthin family, originally purified from plant extracts. It is currently under investigation as a potential therapeutic for multiple myeloma. S-3114 acts by inhibiting the Phosphoinositide 3-Kinase (PI3K)/Akt signaling pathway, which leads to cell cycle arrest at the G2/M phase and the induction of apoptosis through the extrinsic pathway, specifically involving the cleavage of caspase 8. Research also indicates that S-3114 disrupts Golgi-mediated secretion, impacting the production and release of Macrophage Inflammatory Protein-1 alpha (MIP-1α), a chemokine critical for the progression of malignant plasma cell diseases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on schweinfurthin-3114.